Route matters: parenteral glucocorticoid in early RA, and getting off it

Design

observational cohort analysis of the Canadian Early Arthritis Cohort, 2007-2023, adjusted multivariable logistic regression

Population

2,222 adults with newly diagnosed rheumatoid arthritis, symptoms under one year, median age 55, baseline CDAI 26

Primary outcome

glucocorticoid use and escalation to advanced therapy at 12 months, by route of glucocorticoid in the first 3 months

Effect

still on glucocorticoid at 12 months: 8% (none), 47% (oral), 26% (parenteral), 63% (both); OR vs no glucocorticoid 9.8 oral, 4.1 parenteral

This analysis of the Canadian Early Arthritis Cohort took 2,222 adults with rheumatoid arthritis of less than a year's duration, excluded those already on steroids or on advanced therapy early, and grouped them by what they received in the first three months: no glucocorticoid in 75%, oral in 19%, parenteral — intra-articular or intramuscular — in 5%, and both in 1%.

At 12 months the difference was substantial. Still on glucocorticoid: 8% of the no-steroid group, 47% of the oral group, 26% of the parenteral group and 63% of those who had both. Adjusted odds of remaining on steroids against no glucocorticoid were 9.8 for oral and 4.1 for parenteral. Escalation to advanced therapy was identical between oral and parenteral at 14%, so the difference was in steroid persistence, not in disease control failing sooner.

Read this as an association, because it is one. Patients given an injection rather than a prescription differ systematically — fewer joints involved, a rheumatologist willing to inject, a service with the capacity — and adjustment cannot remove all of that. The mechanism is nonetheless plausible and familiar: an injection has a natural end, while an oral course requires someone to actively stop it, and nobody does at a busy clinic when the patient feels well. If your service has the capacity to inject, that is a reason to prefer it in early disease; if it does not, the transferable lesson is to write the stop date on the prescription at the moment you write the drug.

• Prefer intra-articular or intramuscular glucocorticoid over an oral course in early RA where the joint distribution allows
• If prescribing orally, set and document the taper and stop date at the point of prescribing
• Review steroid status explicitly at 3, 6 and 12 months rather than waiting for it to come up
• The combined oral-plus-parenteral group did worst on persistence — treat that pattern as a warning sign
• Advanced therapy escalation did not differ by route, so the choice is not trading steroid exposure for later biologic use

The statistics, in plain English

The odds ratios (9.8 oral, 4.1 parenteral) are against a no-steroid reference, so they mostly reflect the obvious — people started on steroids stay on them — and the interesting comparison is between the two routes, which the raw percentages give more honestly than the ratios do. This is an observational cohort, so route was chosen by clinicians, and the patients they chose to inject were probably different from those they chose to treat orally in ways the model could not capture. Only 121 patients received parenteral glucocorticoid, so the 26% figure is based on a small group.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.